New research shows it’s possible to edit the DNA of human embryos with more precision. But scientists warn it’s still not ...
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for ...